Results 61 to 70 of about 44,979 (214)

A case of spontaneous pneumothorax, pneumomediastinum & subcutaneous emphysema in Pneumocystis jirovecii pneumonia complicating HIV

open access: yesSri Lankan Journal of Infectious Diseases, 2015
Spontaneous pneumothorax and subcutaneous emphysema are well-known but less common complications of pneumocystis pneumonia, whereas pnuemomediastinum is rare.
S Chatterji   +6 more
doaj   +1 more source

Virtual Screening of Phytochemicals to Novel Target (HAT) Rtt109 in Pneumocystis Jirovecii using Bioinformatics Tools [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2016
Introduction: Pneumocystis jirovecii is a fungus that causes Pneumocystis pneumonia in HIV and other immunosuppressed patients. Treatment of Pneumocystis pneumonia with the currently available antifungals is challenging and associated with ...
Ramya Sugumar   +4 more
doaj   +1 more source

Pneumocystis carinii pneumonia in renal transplant recipients treated with cyclosporin [PDF]

open access: yes, 1989
Four cases of pneumocystis carinii pneumonia occurred among 38 renal transplant recipients. Diagnosis was confirmed by cyst concentration technique in 2 cases.
中根, 佳宏   +11 more
core  

Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions [PDF]

open access: yes, 2010
Jose G Castro1, Maya Morrison-Bryant21Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA; 2Jackson Memorial Hospital/University of Miami Infectious Diseases Fellowship Program, Miami, Florida, USAAbstract:
Jose G Castro, Maya Morrison-Bryant
core   +2 more sources

An Update on Invasive Fungal Infections in Solid Organ Transplant Recipients

open access: yesTransplant Infectious Disease, EarlyView.
ABSTRACT Invasive fungal infections (IFI) remain a significant infection‐related complication in solid organ transplant recipients (SOTRs), the incidence of which has not changed overtime. With a focus on studies and data published after 2019, this narrative review provides an update on the epidemiology and prevention of IFIs in SOTRs and highlights ...
Tina Marinelli, Shahid Husain
wiley   +1 more source

Pneumocystis Pneumonia During Medicamentous Treatment of Cushing’s Syndrome – A Description of Two Cases

open access: yesActa Medica, 2011
Only a few cases of pneumocystis pneumonia (PCP) in Cushing’s syndrome have been published in the literature so far. In the majority of these patients, the pneumonia occurred after reduction of the hypercortisolism with medicamentous treatment. We report
Filip Gabalec   +6 more
doaj   +1 more source

Environmental Risk Factors for Pneumocystis Pneumonia Hospitalizations in HIV Patients [PDF]

open access: yes, 2012
Background. Pneumocystis pneumonia (PcP) is the second leading cause of morbidity and mortality in human immunodeficiency virus (HIV)–infected patients in the United States.
Djawe, K   +10 more
core   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

open access: yesInternational Journal of Cancer, Volume 158, Issue 10, Page 2674-2683, 15 May 2026.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang   +5 more
wiley   +1 more source

Quantitative Economic Evaluations of HIV-Related Prevention and Treatment Services: A Review [PDF]

open access: yes, 1994
Dr. Holtgrave and colleagues at the CDC set forth an extensive taxonomy of HIV prevention and treatment services and review reports of efforts to subject some of those services to formal economic evaluation.
Holtgrave, David R.   +2 more
core   +2 more sources

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

open access: yesPediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy